http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
건강한 지원자에 있어서 염산테르비나핀 함유 라미실정과 무조날정의 약물동력학적 비교
최한곤(Han Gon Choi),용철순(Chul Soon Yong),이종달(Jong Dhal Rhee),우종수(Jong Soo Woo),이경희(Kyung Hee Lee),유봉규(Bong Kyu Yoo) 대한약학회 2005 약학회지 Vol.49 No.4
Financial standing of National Health Insurance has been experiencing a grave deterioration during the last 4-5 years, and the yearly amount paid by the insurance for drug expense rose up to 4 trillion won recently. Furthermore, the ratio of drug expenses in the total expenditure of the insurance reached about 25%, showing the tendency to be levelled off. As a measure to improve the financial deterioration of the insurance and to encourage generic substitution among the health professionals, we compared pharmacokinetic parameters of brand name drug (Lamisil) and generic drug (Muzonal) containing terbinafine HCl in healthy volunteers. The area under the curve (AUC) of the two drugs showed 2220.4 ± 784.7 and 2143.1±861.6hr.mg/㎖ in the corresponding order and no statistically significant difference was identified. The peak concentration (Cmax) of the generic drug demonstrated 566.6±246.2 ng/㎖ compared to 550.8±204.0 of brand name drug, which was not significantly different either. Time to reach peak concentration showed about 6 minutes difference between the drugs, which has no clinical significance to the treatment of dermatomycosis and dermatophytosis.